Proxima files radiation therapy device with FDA:
This article was originally published in Clinica
Proxima Therapeutics has submitted its GliaSite RTS radiation treatment for brain tumours to the US FDA for 510(k) marketing clearance. The device consist of a balloon catheter filled with Iotrex, a proprietary liquid radiation source. It is inserted into the hollow space created by the surgical removal of a malignant brain tumour, where it can deliver radiation directly to the tissue surrounding the cavity - the area where tumours are most likely to recur, said the Alpharetta, Georgia company.